SK287382B6 - Očkovacia kompozícia - Google Patents

Očkovacia kompozícia Download PDF

Info

Publication number: SK287382B6
Authority: SK; Slovakia
Prior art keywords: xaa; information; key; note; place
Prior art date: 1999-03-04

Application number

SK1240-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK12402001A3 (sk

Inventor

Birger Srensen

Original Assignee

Bionor Immuno As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-04

Filing date

2000-03-02

Publication date

2010-08-09

2000-03-02 Application filed by Bionor Immuno As filed Critical Bionor Immuno As

2002-02-05 Publication of SK12402001A3 publication Critical patent/SK12402001A3/sk

2010-08-09 Publication of SK287382B6 publication Critical patent/SK287382B6/sk

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 33
239000000203 mixture Substances 0.000 title claims abstract description 16
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 83
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
239000002671 adjuvant Substances 0.000 claims abstract description 21
150000001408 amides Chemical class 0.000 claims abstract description 7
230000003308 immunostimulating effect Effects 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 4
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 3
125000003277 amino group Chemical group 0.000 claims abstract description 3
239000003085 diluting agent Substances 0.000 claims abstract description 3
239000003102 growth factor Substances 0.000 claims description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
235000001014 amino acid Nutrition 0.000 description 65
150000001413 amino acids Chemical class 0.000 description 65
239000000427 antigen Substances 0.000 description 18
108091007433 antigens Proteins 0.000 description 18
102000036639 antigens Human genes 0.000 description 18
101710205625 Capsid protein p24 Proteins 0.000 description 17
101710177166 Phosphoprotein Proteins 0.000 description 17
101710149279 Small delta antigen Proteins 0.000 description 17
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 17
208000031886 HIV Infections Diseases 0.000 description 16
241000713772 Human immunodeficiency virus 1 Species 0.000 description 15
FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
238000004458 analytical method Methods 0.000 description 9
208000030507 AIDS Diseases 0.000 description 8
239000004927 clay Substances 0.000 description 8
238000011161 development Methods 0.000 description 8
241000725303 Human immunodeficiency virus Species 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000037396 body weight Effects 0.000 description 6
239000000969 carrier Substances 0.000 description 6
108010067216 glycyl-glycyl-glycine Proteins 0.000 description 6
108010050848 glycylleucine Proteins 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
241000700605 Viruses Species 0.000 description 5
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
230000028993 immune response Effects 0.000 description 5
238000004989 laser desorption mass spectroscopy Methods 0.000 description 5
238000004949 mass spectrometry Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 4
LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 4
108010079364 N-glycylalanine Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012458 free base Substances 0.000 description 4
108010062266 glycyl-glycyl-argininal Proteins 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 3
WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 3
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 3
WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
230000036039 immunity Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000002245 particle Substances 0.000 description 3
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
229940124718 AIDS vaccine Drugs 0.000 description 2
QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 2
BYLSYQASFJJBCL-DCAQKATOSA-N Asn-Pro-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BYLSYQASFJJBCL-DCAQKATOSA-N 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 2
QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
229940033330 HIV vaccine Drugs 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
BAJIJEGGUYXZGC-CIUDSAMLSA-N Leu-Asn-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N BAJIJEGGUYXZGC-CIUDSAMLSA-N 0.000 description 2
FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 2
PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 2
HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 2
RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 2
AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 2
QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 2
AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 2
GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 2
AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 2
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 2
DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 2
PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
108010068265 aspartyltyrosine Proteins 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
108010038320 lysylphenylalanine Proteins 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
108010077112 prolyl-proline Proteins 0.000 description 2
108010079317 prolyl-tyrosine Proteins 0.000 description 2
229940021993 prophylactic vaccine Drugs 0.000 description 2
230000004044 response Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229940021747 therapeutic vaccine Drugs 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 1
TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
JSLGXODUIAFWCF-WDSKDSINSA-N Arg-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O JSLGXODUIAFWCF-WDSKDSINSA-N 0.000 description 1
YHZQOSXDTFRZKU-WDSOQIARSA-N Arg-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N)=CNC2=C1 YHZQOSXDTFRZKU-WDSOQIARSA-N 0.000 description 1
NMTANZXPDAHUKU-ULQDDVLXSA-N Arg-Tyr-Lys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 NMTANZXPDAHUKU-ULQDDVLXSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
235000019750 Crude protein Nutrition 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
101150040523 EN gene Proteins 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
YIWFXZNIBQBFHR-LURJTMIESA-N Gly-His Chemical compound [NH3+]CC(=O)N[C@H](C([O-])=O)CC1=CN=CN1 YIWFXZNIBQBFHR-LURJTMIESA-N 0.000 description 1
IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 1
QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 1
NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
BBIXOODYWPFNDT-CIUDSAMLSA-N Ile-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O BBIXOODYWPFNDT-CIUDSAMLSA-N 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 1
VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
NLOZZWJNIKKYSC-WDSOQIARSA-N Lys-Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 NLOZZWJNIKKYSC-WDSOQIARSA-N 0.000 description 1
GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 description 1
VUTWYNQUSJWBHO-BZSNNMDCSA-N Lys-Leu-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VUTWYNQUSJWBHO-BZSNNMDCSA-N 0.000 description 1
UQJOKDAYFULYIX-AVGNSLFASA-N Lys-Pro-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 UQJOKDAYFULYIX-AVGNSLFASA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 1
FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
IWAVRIPRTCJAQO-HSHDSVGOSA-N Thr-Pro-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IWAVRIPRTCJAQO-HSHDSVGOSA-N 0.000 description 1
YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
YCQXZDHDSUHUSG-FJHTZYQYSA-N Trp-Thr-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 YCQXZDHDSUHUSG-FJHTZYQYSA-N 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229940037003 alum Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
101150030339 env gene Proteins 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
108010020688 glycylhistidine Proteins 0.000 description 1
108010015792 glycyllysine Proteins 0.000 description 1
108010081551 glycylphenylalanine Proteins 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
108010032806 molgramostim Proteins 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012770 revaccination Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108010026333 seryl-proline Proteins 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000048 toxicity data Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000013598 vector Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
AIDS & HIV (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

SK1240-2001A 1999-03-04 2000-03-02 Očkovacia kompozícia SK287382B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NO19991078A NO311807B1 (no)	1999-03-04	1999-03-04	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
PCT/NO2000/000075 WO2000052040A1 (en)	1999-03-04	2000-03-02	Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv

Publications (2)

Publication Number	Publication Date
SK12402001A3 SK12402001A3 (sk)	2002-02-05
SK287382B6 true SK287382B6 (sk)	2010-08-09

Family

ID=19903050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1240-2001A SK287382B6 (sk)	1999-03-04	2000-03-02	Očkovacia kompozícia

Country Status (23)

Country	Link
US (4)	US6706859B1 (de)
EP (1)	EP1159298B1 (de)
JP (5)	JP2002541069A (de)
CN (4)	CN101328208A (de)
AT (1)	ATE397014T1 (de)
AU (1)	AU771827B2 (de)
BR (1)	BR0008741A (de)
CA (1)	CA2363947C (de)
CY (1)	CY1108299T1 (de)
CZ (1)	CZ300505B6 (de)
DE (1)	DE60039036D1 (de)
DK (1)	DK1159298T3 (de)
EA (1)	EA004802B9 (de)
ES (1)	ES2307496T4 (de)
HK (1)	HK1044778B (de)
HU (1)	HU229282B1 (de)
ID (1)	ID30497A (de)
NO (1)	NO311807B1 (de)
NZ (4)	NZ514619A (de)
PT (1)	PT1159298E (de)
SK (1)	SK287382B6 (de)
WO (1)	WO2000052040A1 (de)
ZA (1)	ZA200107072B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL150961A0 (en)	2000-02-04	2003-02-12	Univ Duke	Human immunodeficiency virus vaccine
NO314588B1 (no)	2000-09-04	2003-04-14	Bionor Immuno As	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) *	2000-09-04	2003-04-14	Bionor Immuno As	HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
PL2392587T3 (pl)	2006-03-10	2016-08-31	Peptcell Ltd	Sekwencje i kompozycje peptydów
KR101701198B1 (ko)	2008-06-19	2017-02-01	배리에이션 바이오테크놀로지스 아이엔씨.	인플루엔자를 치료하기 위한 조성물 및 방법
CA2803282C (en)	2009-07-06	2018-05-01	David E. Anderson	Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh)	2009-07-06	2017-02-08	变异生物技术公司	制备囊泡的方法和由其产生的制剂
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
CN103096922B (zh)	2010-07-06	2019-08-06	变异生物技术公司	用于治疗流行性感冒的组合物和方法
CN103282375B (zh) *	2010-12-02	2017-01-11	比奥诺尔免疫有限公司	肽支架设计
BR112013017939B1 (pt)	2011-01-13	2022-11-16	Variation Biotechnologies Inc	Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de)	2011-10-27	2013-05-01	Christopher L. Parks	Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2802353A4 (de)	2012-01-12	2015-12-02	Variation Biotechnologies Inc	Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh)	2012-01-27	2020-03-31	变异生物技术公司	用于治疗剂的方法和组合物
MX2014014683A (es)	2012-06-06	2015-02-24	Bionor Immuno As	Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
CA2875624A1 (en) *	2012-06-06	2013-12-12	Bionor Immuno As	Hiv vaccine
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
WO2015007337A1 (en)	2013-07-19	2015-01-22	Bionor Immuno As	Method for the vaccination against hiv
WO2015022401A1 (en) *	2013-08-14	2015-02-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Immunoadjuvant compositions and uses thereof
EP2848937A1 (de)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Lösliche hiv-1-hüllglykoproteintrimere
WO2015086738A2 (en) *	2013-12-11	2015-06-18	Bionor Immuno As	Hiv vaccine
AU2015208033B2 (en)	2014-01-27	2019-02-07	Bionor Immuno As	Method for the vaccination against HIV
WO2015110659A1 (en) *	2014-01-27	2015-07-30	Bionor Immuno As	Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
EP3099318A1 (de)	2014-01-27	2016-12-07	Bionor Immuno AS	Dosierungsschema für hiv-impfstoff
US10407464B2 (en) *	2014-04-03	2019-09-10	Amgen Inc.	Method for preparing AMG 416
WO2016005508A1 (en)	2014-07-11	2016-01-14	Bionor Immuno As	Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US20180140694A1 (en)	2015-05-04	2018-05-24	Bionor Immuno As	Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0230222A1 (de)	1986-01-06	1987-07-29	F. Hoffmann-La Roche Ag	Expression des HTLV-III Gag-Gens
US4925784A (en)	1986-04-04	1990-05-15	Hoffmann-La Roche Inc.	Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en)	1986-12-05	1987-01-14	Hoffmann La Roche	Env/gag polypeptides
IE63455B1 (en)	1987-09-04	1995-04-19	Int Murex Tech Corp	Immunoassay and biological constructs for use therein
US4888290A (en) *	1987-11-06	1989-12-19	Coulter Corporation	Monoclonal antibody specific to HIV antigens
EP0356007A3 (de) *	1988-07-22	1991-07-03	Medical Research Council	Antigenische Determinanten
KR940000755B1 (ko) *	1990-02-16	1994-01-29	유나이티드 바이오메디칼 인코오포레이티드	Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv)	1990-02-20	1992-11-16	Replico Medical Ab	Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) *	1992-09-14	1994-02-22	The Regents Of The University Of California	Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) *	1993-03-31	1996-09-06	Fernand Narbey Torossian	Complexe immunomodulateur anti SIDA.
WO1994028871A1 (en) *	1993-06-07	1994-12-22	Endocon, Inc.	Implant stimulated cellular immunity
AU685521B2 (en) *	1993-10-19	1998-01-22	Ajinomoto Co., Inc.	Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
FR2731013B1 (fr) *	1995-02-27	1997-05-16	Inst Nat Sante Rech Med	Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
ES2187947T5 (es)	1997-03-10	2014-01-29	Roche Diagnostics Gmbh	Procedimiento para la detección simultánea de antígenos de HIV y anticuerpos de HIV

1999
- 1999-03-04 NO NO19991078A patent/NO311807B1/no not_active IP Right Cessation
2000
- 2000-03-02 WO PCT/NO2000/000075 patent/WO2000052040A1/en not_active Ceased
- 2000-03-02 HU HU0200265A patent/HU229282B1/hu not_active IP Right Cessation
- 2000-03-02 CZ CZ20013195A patent/CZ300505B6/cs not_active IP Right Cessation
- 2000-03-02 CA CA002363947A patent/CA2363947C/en not_active Expired - Fee Related
- 2000-03-02 CN CNA2008100921330A patent/CN101328208A/zh active Pending
- 2000-03-02 ID IDW00200102137A patent/ID30497A/id unknown
- 2000-03-02 NZ NZ514619A patent/NZ514619A/en not_active IP Right Cessation
- 2000-03-02 NZ NZ525752A patent/NZ525752A/en not_active IP Right Cessation
- 2000-03-02 ES ES00911492T patent/ES2307496T4/es not_active Expired - Lifetime
- 2000-03-02 CN CNA2008100921311A patent/CN101328209A/zh active Pending
- 2000-03-02 DE DE60039036T patent/DE60039036D1/de not_active Expired - Lifetime
- 2000-03-02 PT PT00911492T patent/PT1159298E/pt unknown
- 2000-03-02 NZ NZ525751A patent/NZ525751A/en not_active IP Right Cessation
- 2000-03-02 HK HK02106292.0A patent/HK1044778B/zh not_active IP Right Cessation
- 2000-03-02 AT AT00911492T patent/ATE397014T1/de active
- 2000-03-02 JP JP2000602264A patent/JP2002541069A/ja active Pending
- 2000-03-02 US US09/674,674 patent/US6706859B1/en not_active Expired - Lifetime
- 2000-03-02 AU AU33358/00A patent/AU771827B2/en not_active Ceased
- 2000-03-02 EP EP00911492A patent/EP1159298B1/de not_active Expired - Lifetime
- 2000-03-02 SK SK1240-2001A patent/SK287382B6/sk not_active IP Right Cessation
- 2000-03-02 DK DK00911492T patent/DK1159298T3/da active
- 2000-03-02 NZ NZ525753A patent/NZ525753A/en not_active IP Right Cessation
- 2000-03-02 EA EA200100943A patent/EA004802B9/ru not_active IP Right Cessation
- 2000-03-02 CN CNA2008100921326A patent/CN101328210A/zh active Pending
- 2000-03-02 CN CNB008057354A patent/CN100387617C/zh not_active Expired - Fee Related
- 2000-03-02 BR BR0008741-6A patent/BR0008741A/pt not_active IP Right Cessation
2001
- 2001-08-27 ZA ZA200107072A patent/ZA200107072B/xx unknown
2003
- 2003-09-11 US US10/659,324 patent/US7311915B2/en not_active Expired - Fee Related
2007
- 2007-10-01 US US11/865,109 patent/US7709004B2/en not_active Expired - Fee Related
- 2007-10-01 US US11/865,106 patent/US7709003B2/en not_active Expired - Fee Related
2008
- 2008-08-28 CY CY20081100922T patent/CY1108299T1/el unknown
2010
- 2010-12-09 JP JP2010275025A patent/JP5313998B2/ja not_active Expired - Fee Related
2012
- 2012-10-31 JP JP2012239940A patent/JP5695010B2/ja not_active Expired - Fee Related
- 2012-10-31 JP JP2012240131A patent/JP5695012B2/ja not_active Expired - Fee Related
2013
- 2013-12-02 JP JP2013249096A patent/JP5814331B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101328209A (zh)	2008-12-24
DE60039036D1 (de)	2008-07-10
CZ300505B6 (cs)	2009-06-03
WO2000052040A1 (en)	2000-09-08
EA004802B9 (ru)	2015-03-31
EP1159298B1 (de)	2008-05-28
NZ525752A (en)	2004-10-29
CN1346367A (zh)	2002-04-24
NZ525751A (en)	2004-10-29
JP5313998B2 (ja)	2013-10-09
US20080107670A1 (en)	2008-05-08
US7709003B2 (en)	2010-05-04
HUP0200265A2 (en)	2002-06-29
JP5814331B2 (ja)	2015-11-17
JP2011074081A (ja)	2011-04-14
AU3335800A (en)	2000-09-21
CA2363947A1 (en)	2000-09-08
CY1108299T1 (el)	2014-02-12
CN101328210A (zh)	2008-12-24
NZ525753A (en)	2004-10-29
SK12402001A3 (sk)	2002-02-05
NO311807B1 (no)	2002-01-28
CN100387617C (zh)	2008-05-14
ATE397014T1 (de)	2008-06-15
CA2363947C (en)	2008-05-20
JP2002541069A (ja)	2002-12-03
JP2013032384A (ja)	2013-02-14
EA004802B1 (ru)	2004-08-26
US20080107669A1 (en)	2008-05-08
US6706859B1 (en)	2004-03-16
CN101328208A (zh)	2008-12-24
HK1044778A1 (en)	2002-11-01
NZ514619A (en)	2003-10-31
ES2307496T3 (es)	2008-12-01
US7709004B2 (en)	2010-05-04
ES2307496T4 (es)	2015-03-06
US20040259797A1 (en)	2004-12-23
DK1159298T3 (da)	2008-08-25
JP5695012B2 (ja)	2015-04-01
PT1159298E (pt)	2008-09-04
JP2013032386A (ja)	2013-02-14
JP2014043468A (ja)	2014-03-13
EA200100943A1 (ru)	2002-02-28
CZ20013195A3 (cs)	2002-02-13
ZA200107072B (en)	2002-11-27
HU229282B1 (en)	2013-10-28
EP1159298A1 (de)	2001-12-05
HK1044778B (zh)	2009-04-24
NO991078D0 (no)	1999-03-04
BR0008741A (pt)	2002-01-08
AU771827B2 (en)	2004-04-01
US7311915B2 (en)	2007-12-25
ID30497A (id)	2001-12-13
NO991078L (no)	2000-09-05
JP5695010B2 (ja)	2015-04-01

Legal Events

Date	Code	Title	Description
2018-12-03	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20180302

Publication	Publication Date	Title
ES2307496T3 (es)	2008-12-01	Composiciones de vacuna, antigenos y peptidos.
US7612168B2 (en)	2009-11-03	Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AU2001282706A1 (en)	2002-06-13	HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
SK4012003A3 (en)	2003-09-11	Regulatory and auxiliary HIV peptides, antigens, vaccine compositions, an immunoassay kit and method of detecting antibodies induced by HIV
HK1124867A (en)	2009-07-24	Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
HK1124865A (en)	2009-07-24	Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv